Table 1.
Baseline characteristics of subjects (N = 301).
| Overall |
No ischemia |
Ischemia |
P-value | |
|---|---|---|---|---|
| n | 301 | 259 | 42 | |
| Demographics | ||||
| Age (yrs.), median [Q1,Q3] | 58.0 [50.0,66.0] | 58.0 [49.0,65.0] | 63.5 [56.0,69.8] | 0.005 |
| Female sex, n (%) | 127 (42.2 %) | 113 (43.6 %) | 14 (33.3 %) | 0.278 |
| Race, n (%) | 0.138 | |||
| White Origins in Europe, Middle East, North Africa | 146 (48.5) | 119 (45.9) | 27 (64.3) | |
| Black/African American | 143 (47.5) | 129 (49.8) | 14 (33.3) | |
| Indigenous and/or Alaskan Native | 5 (1.7) | 5 (1.9) | ||
| Mixed race | 4 (1.3) | 4 (1.5) | ||
| Asian | 3 (1.0) | 2 (0.8) | 1 (2.4) | |
| Ethnicity, n (%) | 0.373 | |||
| Not Hispanic or Latino | 290 (96.3) | 248 (95.8) | 42 (100.0) | |
| Hispanic or Latino or Spanish origin | 11 (3.7) | 11 (4.2) | ||
| Cardiovascular risk factors | ||||
| BMI, median [Q1,Q3] | 30.9 [26.8,35.4] | 30.9 [26.7,35.8] | 30.5 [26.8,34.0] | 0.867 |
| Diabetes, n (%) | 68 (22.6) | 56 (21.6) | 12 (28.6) | 0.424 |
| Hypertension, n (%) | 217 (72.1) | 184 (71.0) | 33 (78.6) | 0.410 |
| Hyperlipidemia, n (%) | 165 (54.8) | 135 (52.1) | 30 (71.4) | 0.030 |
| Current or former smoker, n (%) | 167 (55.5) | 141 (54.4) | 26 (61.9) | 0.462 |
| Family history of CVD, n (%) | 100 (33.2) | 80 (30.9) | 20 (47.6) | 0.050 |
| Medications, n (%) | ||||
| Statins | 127 (42.2) | 104 (40.2) | 23 (54.8) | 0.107 |
| Beta blockers | 113 (37.5) | 89 (34.4) | 24 (57.1) | 0.008 |
| Aspirin | 85 (28.2) | 68 (26.3) | 17 (40.5) | 0.086 |
| Calcium channel blockers | 64 (21.3) | 52 (20.1) | 12 (28.6) | 0.296 |
| ACE-I/ARB | 53 (17.6) | 50 (19.3) | 3 (7.1) | 0.089 |
| Nitrates | 48 (15.9) | 35 (13.5) | 13 (31.0) | 0.008 |
| Prior cardiac interventions, mean (SD) | ||||
| Number of previous stents | 2.4 (1.9) | 1.9 (1.4) | 3.4 (2.4) | 0.019 |
This table depicts the demographics and baseline characteristics of the two groups where ischemia was defined as ≥70 % epicardial coronary artery stenosis, revascularization within 30 days, or 30-day major adverse cardiac events (MACE).